

Breno Amaral Rocha 0000-0002-3695-9374

Giovanna Ribeiro Souto 0000-0003-3617-8794

Soraya de Mattos Camargo Grossmann 0000-0002-8920-3853

Paulo Eduardo Alencar Souza 0000-0001-5166-1982

Rodrigo Villamarim Soares 0000-0001-7698-7532

Martinho Campolina Rebello Horta 0000-0003-0192-5614

<https://doi.org/10.5327/2525-5711.276>

Review Article

**Oropouche fever: An emerging
arbovirus disease from the Americas
with possible oral manifestations**

Breno Amaral Rocha^{1,2}

Giovanna Ribeiro Souto¹

Soraya de Mattos Camargo Grossmann¹

Paulo Eduardo Alencar Souza¹

Rodrigo Villamarim Soares¹

Martinho Campolina Rebello Horta^{1*}

¹Pontifícia Universidade Católica de Minas Gerais, Graduate Program in Dentistry – Belo Horizonte (MG), Brazil.

²Centro Universitário FIPMoc, Department of Dentistry – Montes Claros (MG), Brazil.

*Correspondence to: E-mail: martinhohorta@pucminas.br

Received on October 30, 2024. Accepted on **December 1, 2024**.

STATEMENT OF CLINICAL SIGNIFICANCE

Oropouche fever is an emerging arbovirus disease with potential for global spreading, with 10,275 confirmed cases in the Americas in 2024. The main clinical manifestations resemble those of common arbovirus diseases. Gingival bleeding has been reported, with oral mucosal lesions as another possible manifestation. The dental community can contribute to prompt diagnosis and management.

Abstract

Oropouche fever (OROV fever) is an emerging arbovirus disease caused by Oropouche virus (OROV). The virus was reported to have a limited circulation in Central and South America, but there is a real

possibility of international spread in the near future. Considering the current outbreak of OROV fever in the Americas, the Pan American Health Organization/World Health Organization has already published one Epidemiological Alert and two Epidemiological Updates in 2024. From January to early October 2024, 10,275 cases were confirmed in nine American countries, including imported cases in the United States and Canada. Moreover, 30 imported cases were reported for the first time in three European countries. Knowledge about OROV fever is still limited. Like common arbovirus diseases, the main clinical manifestations include fever, headache, arthralgia, myalgia, bleeding and rash. Gingival bleeding has been reported, and oral mucosal lesions may be another possible manifestation. The disease is usually mild and self-limiting, but severe complications, death and vertical transmission can occur. This article reviews OROV fever, addressing possible oral manifestations as well as the potential contribution of the dental community to prompt diagnosis and management.

Keywords: arbovirus infections, dentistry, gingival hemorrhage, oral mucosa, Oropouche fever.

INTRODUCTION

Arboviruses (arthropod-borne viruses) are a large group of zoonotic RNA viruses that circulate between vertebrate hosts (including humans as incidental hosts), and hematophagous arthropod vectors (such as mosquitoes, midges, sandflies and ticks)^{1,2}. The most prevalent arbovirus diseases worldwide are dengue fever (nearly 96 million cases per year), chikungunya (nearly 693,000 cases per year), and Zika (nearly 500,000 cases per year)³.

Emerging infectious diseases can be defined as newly appearing infections in a population, or previously existing diseases showing fast growth in incidence or geographical range⁴. The emergence of arbovirus diseases' pandemic potential is an increasing global public health concern, since the geographical range of arboviruses is continually rising due to human mobility, urban sprawl, ecological adaptation of vectors due to climate change, and uncontrolled vector population growth⁵.

In 2024, we are facing an unprecedented outbreak of Oropouche fever (OROV fever), an emerging arbovirus disease from the Americas caused by the Oropouche virus (OROV). From January to early October 2024, a total of 10,275 cases were reported in nine American countries (including imported cases in the United States and Canada), and 30 imported cases were detected for the first time in three European countries⁶⁻⁸.

In this context, this article reviews OROV fever and the most prevalent arbovirus diseases co-circulating in the same areas and showing similar clinical presentation. This review discusses possible oral manifestations and the potential contribution of the dental community to prompt diagnosis and management of these public health threats.

LITERATURE REVIEW/DISCUSSION

Oropouche virus (OROV)

Oropouche virus (OROV), which causes OROV fever, is an arbovirus of the Orthobunyavirus genus in the *Peribunyaviridae* family, mainly transmitted by biting midges of the species *Culicoides paraensis*, as well as by certain mosquito vectors. Since OROV was first detected in 1955 in the community of Vega de Oropouche, Trinidad and Tobago, nearly 500,000 cases have been reported. Still, knowledge about OROV fever remains limited. The virus was reported to have limited circulation in Central and South America, close to forested areas, in a sylvatic cycle with mammals and birds as natural reservoirs. However, an alarming urban cycle of the disease, distant from forests, has also been reported, with humans as vertebrate hosts. This shift in spread is associated with climate change, deforestation, and human and animal mobility, as well as with genetic alterations in the virus⁹⁻¹⁵.

The current Oropouche virus fever outbreak and the risk of international spreading

Considering the current outbreak of OROV fever in the Americas, the Pan American Health Organization/World Health Organization (PAHO/WHO) published an Epidemiological Alert on August 1, 2024, followed by two Epidemiological Updates on September 6 and October 15, 2024⁶⁻⁸. A total of 10,275 cases of OROV fever were confirmed in 2024 from epidemiological weeks 1 to 40 in nine countries: Brazil (8,258 cases, including two deaths), Peru (936 cases), Cuba (555 cases), Bolivia (356 cases), the United States (90 imported cases), Colombia (74 cases), Canada

(2 imported cases), Ecuador (2 cases), and Guyana (2 cases). In Brazil, the most affected country in the current outbreak, 70% of the 8,258 laboratory-confirmed cases were reported in seven states of the Amazon region, an area considered endemic for OROV fever. However, 15 non-Amazonian Brazilian states also reported autochthonous transmission, some for the first time⁸.

Since large human movements across the globe enhance the risk of emerging viruses spreading across international borders, worldwide healthcare professionals must consider OROV fever among the diagnostic possibilities of fever in returning travelers¹⁶. In August 2024, the US Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory to notify clinicians and public health authorities about the current OROV fever outbreak in the Americas and the associated risk to travelers¹⁷. Additionally, from epidemiological weeks 23 to 39 of 2024, PAHO/WHO reported 30 imported cases for the first time in three European countries: Spain (21 cases), Italy (6 cases), and Germany (3 cases). Of these patients, 20 had travelled to Cuba and one to Brazil⁸.

The epidemiological natural history of OROV fever indicates that climate and environmental changes impact the spatial dispersion of hosts and vectors. In fact, since ecological, climatic, and demographic changes are a worldwide phenomenon, there is a real possibility that OROV will spread outside the Americas in the near future^{12,14}. In this context, a recently published study based in genomic and epidemiological analyses provided a view of the unprecedented evolution and spread of OROV in the current outbreak in Brazil's western Amazon, caused by a novel reassortant OROV lineage, confirming the high epidemic potential of this arbovirus and raising major concerns about the risk of OROV spreading beyond the previously affected regions¹⁸. Another recent study also suggests that the present re-emergence of OROV fever in Brazil may be associated with a new OROV reassortant, with faster replication, and the ability to evade antibodies of individuals previously infected with the ordinary virus. To be prepared for a potential OROV fever epidemic, this study reinforces the need to monitor OROV strains capable of escaping immunity, as well as develop vaccines against OROV and its reassortants¹⁹.

Clinical overview of the disease

OROV fever is usually mild and self-limiting, typically resolving within one week. Similar to other common arbovirus diseases such as dengue fever, chikungunya, and Zika, the main clinical manifestations of OROV fever are fever, headache, arthralgia, myalgia, malaise, nausea, vomiting, chills, dizziness, photophobia, retro-orbital pain, bleeding and rash. Rarely, severe complications such as meningitis and encephalitis may occur. The diagnosis is clinical, epidemiological and laboratorial, and symptomatic treatment is offered⁶⁻¹⁵. There are no approved vaccines or specific antiviral medications to prevent OROV infection or to treat OROV fever^{12,13,19}. The first deaths due to the disease, which were reported in the current outbreak, occurred in two young Brazilian women, neither with comorbidity^{6-8,12,20}.

In the current outbreak, there are also concerns over possible vertical (mother-to-child) transmission, since fetal deaths and birth defects such as microcephaly are being investigated^{12,21}. In fact, up to epidemiological week 40 of 2024, Brazilian health authorities have confirmed one case of fetal death and one case of congenital anomaly, and another 12 fetal deaths, three spontaneous miscarriages, and three newborns with congenital anomalies are under investigation. Moreover, in Cuba, one case of congenital anomaly was confirmed in September 2024, and another two cases are under investigation⁸.

Since most clinical information is derived from case reports or minor outbreaks, the clinical features of OROV fever are poorly described. Furthermore, morbidity and mortality could be underestimated¹³.

Possible oral manifestations

Concerning oral manifestations, gingival bleeding has been reported in at least two different OROV fever outbreaks^{22,23}. In the 2007–2008 OROV fever outbreak in Manaus (Brazil), 20 of the 128 patients (15%) showed spontaneous hemorrhagic phenomena, including petechiae, epistaxis, and gingival bleeding²². Additionally, cases showing hemorrhagic phenomena characterized by epistaxis, gingival bleeding, and menorrhagia were reported in the 2010 OROV fever outbreak in Bagazan (Peru)²³. It is important to highlight that gingival bleeding is listed as a hemorrhagic symptom of OROV fever in multiple health authorities' official documents^{6-8,15,24,25}.

Even though, to the best of our knowledge, no reports have specifically described oral mucosal lesions in patients with OROV fever, it is noteworthy that mucosal ulcers are a common finding in viral-related rashes, including arbovirus diseases²⁶. In this regard, a cross-sectional study of a Brazilian population showed association between endemic arbovirus diseases and ulcerated oral lesions²⁷. Therefore, in addition to the already reported gingival bleeding, there is a possibility that oral mucosal lesions in OROV fever patients could be described in future reports of the disease.

Arbovirus diseases co-circulate and must be detected early

Adding more complexity to the situation, it is noteworthy that co-circulation, co-transmission, and co-infection of arboviruses in urban and surrounding areas has become a major concern for global public health²⁸.

In this context, **Table 1**^{6-15,21-26,29-31} **Table 1.** Etiology, transmission, skin rash and oral manifestations of Oropouche fever and the most prevalent arbovirus diseases worldwide.

Arbovirus disease	Etiology	Transmission	Skin rash	Oral manifestations
Dengue fever ^{26,29-31}	dengue vírus (DENV)	Main vector: mosquitoes (<i>Aedes</i> spp.). Potential for vertical and blood-borne transmission, but no sexual transmission.	Maculopapular or morbilliform rash (“isles of white on a sea of red”) that begins on hands and feet and	Aphthous-like ulcers, oropharyngeal erythema, petechiae, gingival bleeding and gingival and
Chikungunya ^{26,29-31}	chikungunya vírus (CHIKV)	Main vector: mosquitoes (<i>Aedes</i> spp.). Potential for vertical and blood-borne transmission, but no sexual transmission.	Maculopapular rash on extremities and trunk that can involve the face.	Aphthous-like ulcers and oral mucosal lesions like Koplik spots.
Zika ^{26,30,31}	Zika vírus (ZIKV)	Main vector: mosquitoes (<i>Aedes</i> spp.). Potential for vertical, blood-borne and sexual transmission.	Maculopapular rash on the face, extremities, and trunk.	Aphthous-like ulcers.
Oropouche fever ^{6-15,21-25}	Oropouche vírus (OROV)	Main vector: midges (<i>Culicoides paraensis</i>). Vertical transmission confirmed in the current outbreak.	Rubella-like rash on the trunk and arms.	Gingival bleeding.

describes important features of the emerging OROV fever and of dengue fever, chikungunya, and Zika, the most prevalent arbovirus diseases worldwide³.

According to the WHO Global Arbovirus Initiative, strengthening early detection of arbovirus diseases, a strategic objective to reduce local risk of epidemics, includes priority actions such as the development or updating of tools for training physicians and other health professionals⁵.

CONCLUSION

OROV fever is an emerging arbovirus disease with potential for global spreading. In 2024, we are facing an unprecedented outbreak of the disease, with more than 10,000 cases in the Americas and, for the first time, imported cases in Europe. The main clinical manifestations are similar to those of other common arbovirus diseases. Gingival bleeding has been reported, and it is possible that oral mucosal lesions will be described in the near future.

The dental community should be aware of the main clinical features and possible oral manifestations of the most common arbovirus diseases, as well as the emerging OROV fever, in order to contribute to prompt diagnosis and management of these public health threats. Finally, researchers and oral care providers must be encouraged to report cases of oral manifestations of OROV fever.

AUTHORS' CONTRIBUTIONS

BAR, RVS and MCRH contributed to the conception and drafted the manuscript. All authors critically revised the manuscript, gave final approval and agree to be accountable for all aspects of the work ensuring integrity and accuracy.

CONFLICT OF INTEREST STATEMENT

Funding: This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. The authors are also grateful to the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and the Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG).

Competing interests: The authors have no relevant financial or non-financial interests to disclose.

REFERENCES

1. Meltzer E. Arboviruses and viral hemorrhagic fevers (VHF). *Infect Dis Clin North Am.* 2012;26(2):479-96.
<https://doi.org/10.1016/j.idc.2012.02.003>

2. Sukhralia S, Verma M, Gopirajan S, Dhanaraj PS, Lal R, Mehla N, et al. From dengue to Zika: the wide spread of mosquito-borne arboviruses. *Eur J Clin Microbiol Infect Dis*. 2019;38(1):3-14. <https://doi.org/10.1007/s10096-018-3375-7>
3. Franklins LHV, Jones KE, Redding DW, Abubakar I. The effect of global change on mosquito-borne disease. *Lancet Infect Dis*. 2019;19(9):e302-e312. [https://doi.org/10.1016/S1473-3099\(19\)30161-6](https://doi.org/10.1016/S1473-3099(19)30161-6)
4. McArthur DB. Emerging infectious diseases. *Nurs Clin North Am*. 2019;54(2):297-311. <https://doi.org/10.1016/j.cnur.2019.02.006>
5. World Health Organization. Global arbovirus initiative: preparing for the next pandemic by tackling mosquito-borne viruses with epidemic and pandemic potential [Internet]. Geneva: WHO; 2024 [cited 2024 October 5] Available from: <https://www.who.int/publications/i/item/9789240088948>
6. Pan American Health Organization. World Health Organization. Epidemiological alert: oropouche in the region of the Americas – 1 August 2024 [Internet]. Washington: PAHO/WHO; 2024 [cited 2024 August 12]. Available from: <https://www.paho.org/en/documents/epidemiological-alert-oropouche-region-americas-1-august-2024>
7. Pan American Health Organization. World Health Organization. Epidemiological update: Oropouche in the Americas region – 6 September 2024 [Internet]. Washington: PAHO/WHO; 2024 [cited 2024 September 30]. Available from: <https://www.paho.org/en/documents/epidemiological-update-oropouche-americas-region-6-september-2024>
8. Pan American Health Organization. World Health Organization. Epidemiological update: Oropouche in the Americas region – 15 October 2024 [Internet]. Washington: PAHO/WHO; 2024 [cited 2024 October 21]. Available from: <https://www.paho.org/en/documents/epidemiological-update-oropouche-americas-region-15-october-2024>
9. Rosa JFT, Souza WM, Pinheiro FP, Figueiredo ML, Cardoso JF, Acrani GO, et al. Oropouche virus: clinical, epidemiological, and molecular aspects of a neglected orthobunyavirus. *Am J Trop Med Hyg*. 2017;96(5):1019-30. <https://doi.org/10.4269/ajtmh.16-0672>
10. Romero-Alvarez D, Escobar LE. Oropouche fever, an emergent disease from the Americas. *Microbes Infect*. 2018;20(3):135-46. <https://doi.org/10.1016/j.micinf.2017.11.013>

11. Sakkas H, Bozidis P, Franks A, Papadopoulou C. Oropouche fever: a review. *Viruses*. 2018;10(4):175. <https://doi.org/10.3390/v10040175>
12. The Lancet Infectious Diseases. Oropouche fever, the mysterious threat. *Lancet Infect Dis*. 2024;24(9):935. [https://doi.org/10.1016/S1473-3099\(24\)00516-4](https://doi.org/10.1016/S1473-3099(24)00516-4)
13. Wesselmann KM, Postigo-Hidalgo I, Pezzi L, Oliveira-Filho EF, Fischer C, Lamballerie X, et al. Emergence of Oropouche fever in Latin America: a narrative review. *Lancet Infect Dis*. 2024;24(7):e439-e452. [https://doi.org/10.1016/S1473-3099\(23\)00740-5](https://doi.org/10.1016/S1473-3099(23)00740-5)
14. Zhang Y, Liu X, Wu Z, Feng S, Lu K, Zhu W, et al. Oropouche virus: a neglected global arboviral threat. *Virus Res*. 2024;341:199318. <https://doi.org/10.1016/j.virusres.2024.199318>
15. Centers for Disease Control and Prevention. Clinical overview of oropouche virus disease [Internet]. Atlanta: CDC; 2024 [cited 2024 October 1]. Available from: <https://www.cdc.gov/oropouche/hcp/clinical-overview/index.html>
16. Capobianchi MR, Castilletti C, Gobbi FG. Potential risks of Oropouche virus importation into Europe. *J Travel Med*. 2024;31(7):taae109. <https://doi.org/10.1093/jtm/taae109>
17. Centers for Disease Control and Prevention. Increased Oropouche virus activity and associated risk to travelers [Internet]. Atlanta: CDC; 2024 [cited 2024 August 31]. Available from: <https://emergency.cdc.gov/han/2024/han00515.asp>
18. Naveca FG, Almeida TAP, Souza V, Nascimento V, Silva D, Nascimento F, et al. Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region. *Nat Med*. 2024. <https://doi.org/10.1038/s41591-024-03300-3>
19. Scachetti GC, Forato J, Claro IM, Hua X, Salgado BB, Vieira A, et al. Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study. *Lancet Infect Dis*. 2024:S1473-3099(24)00619-4. [https://doi.org/10.1016/S1473-3099\(24\)00619-4](https://doi.org/10.1016/S1473-3099(24)00619-4)
20. Bandeira AC, Pereira FM, Leal A, Santos SPO, Barbosa AC, Souza MSPL, et al. Fatal Oropouche virus infections in nonendemic region, Brazil, 2024. *Emerg Infect Dis*. 2024;30(11):2370-4. <https://doi.org/10.3201/eid3011.241132>

21. Martins-Filho PR, Carvalho TA, Santos CA. Oropouche fever: reports of vertical transmission and deaths in Brazil. *Lancet Infect Dis.* 2024;24(11):e662-e663. [https://doi.org/10.1016/S1473-3099\(24\)00557-7](https://doi.org/10.1016/S1473-3099(24)00557-7)
22. Mourão MP, Bastos MS, Gimaqu JBL, Mota BR, Souza GS, Grimmer GHN, et al. Oropouche fever outbreak, Manaus, Brazil, 2007-2008. *Emerg Infect Dis.* 2009;15(12):2063-4. <https://doi.org/10.3201/eid1512.090917>
23. Alvarez-Falconi PP, Ríos Ruiz BA. Brote de fiebre de oropouche en bagazán, San Martín Perú: evaluación epidemiológica, manifestaciones gastrointestinales y hemorrágicas. *Rev Gastroenterol Perú.* 2010;30(4):334-40.
24. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Departamento de Doenças Transmissíveis. Coordenação-Geral de Vigilância de Arboviroses. Nota Técnica nº 6/2024-CGARB/DEDT/SVSA/MS. Orientações para a vigilância da Febre do Oropouche [Internet]. Brasília: Ministério da Saúde; 2024 [cited 2024 October 25]. Available from: <https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/notas-tecnicas/2024/nota-tecnica-no-6-2024-cgarb-dedt-svsa-ms/view>
25. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Departamento de Doenças Transmissíveis. Coordenação-Geral de Vigilância de Arboviroses. Nota Técnica Conjunta nº 135/2024-SVSA/SAPS/SAES/MS. Orientações para notificação e investigação de casos suspeitos de Oropouche em gestantes, anomalias congênitas ou óbitos fetais [Internet]. Brasília: Ministério da Saúde; 2024 [cited 2024 October 25]. Available from: <https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/notas-tecnicas/2024/nota-tecnica-conjunta-no-135-2024-svsa-saps-saes-ms/view>
26. Castro MCR, Ramos-E-Silva M. The rash with mucosal ulceration. *Clin Dermatol.* 2020;38(1):35-41. <https://doi.org/10.1016/j.clindermatol.2019.10.019>
27. Barros AM, Martins-de-Barros AV, Costa MJ, Sette-de-Souza PH, Lucena EE, Araújo FA. Prevalence of ulcerative stomatitis in arbovirus infections in a Brazilian Northeast population. *Med Oral Patol Oral Cir Bucal.* 2020;25(6):e810-e817. <https://doi.org/10.4317/medoral.23865>

28. Alves RPS, Amorim JH. Editorial: Arboviruses: co-circulation, co-transmission, and co-infection. *Front Microbiol.* 2023;14:1321166. <https://doi.org/10.3389/fmicb.2023.1321166>
29. Scully C, Samaranayake LP. Emerging and changing viral diseases in the new millennium. *Oral Dis.* 2016;22(3):171-9. <https://doi.org/10.1111/odi.12356>
30. Drago F, Ciccarese G, Gasparini G, Cogorno L, Javor S, Toniolo A, et al. Contemporary infectious exanthems: an update. *Future Microbiol.* 2017;12:171-93. <https://doi.org/10.2217/fmb-2016-0147>
31. Gonzales Y Tucker RD, Addepalli A. Fever and rash. *Emerg Med Clin North Am.* 2024;42(2):303-34. <https://doi.org/10.1016/j.emc.2024.01.005>

In Press